Human Organoids Market by Product (Pancreas, Kidney, Lung, GIT, Liver Models) Usabilty (Customized, Ready-To-Use), Application (Toxicity, Pathology, Personalized & Regenerative Medicine), Enduser (Pharma-Biotech, CROs, Academia) - Global Forecast to 2025
The human organoids market is projected to reach USD 1,901 million by 2025, growing at a CAGR of 17.5%. Key growth drivers include technological advancements, an increasing number of transplants, and rising public-private funding. The market is driven by a focus on developing alternatives to animal testing, addressing issues with traditional animal models in drug response prediction. However, the market faces challenges such as a lack of infrastructure for 3D cell culture and a shortage of skilled professionals. The liver segment is expected to hold the largest market share due to advancements in technology and the growing incidence of liver diseases. North America is the leading regional market, with major players like BioIVT, Thermo Fisher Scientific, and Corning contributing significantly. Recent developments include strategic partnerships and collaborations aimed at enhancing organoid applications in drug discovery and regenerative medicine.
To know about the assumptions considered for the study, Request for Free Sample Report
Clinical Microbiology Market Dynamics
Drivers: Growing focus on developing alternatives for animal testing models
Animal models are widely used in biomedical research for human-specific diseases. However, there are various cases that demonstrate that animal models cannot always be predictive for human drug response, like in the case of drug toxicology studies. This is because there are wide variations in the metabolism of drugs and toxins in humans as compared to animals, which makes it nearly impossible to study drug metabolism in experimental models such as laboratory rodent species. Additionally, in recent years, several regulations have been implemented that restrict the use of animals in research activities globally. Similarly, several bodies, such as Cruelty Free International and the Fund for the Replacement of Animals in Medical Experiments, oppose the use of animal-based models for research purposes.
It is necessary to develop alternative testing models that can provide an environment with maximum equivalence to that of the human body. Considering this, various institutes are involved in developing alternative methods for drug development and biomedical research. As organoids can serve as alternatives to animal models, the current focus on reducing animal use in research is expected to support the growth of the human organoids market.
Restraints: Issues related to the incorporation of organoids into existing workflows
The lack of infrastructure for 3D cell culture research is significantly limiting the overall growth of the organoids market. The availability of the necessary equipment to use advanced techniques is one of the prerequisites for conducting 3D cell culture-based research. Moreover, various technical challenges are involved in incorporating organoids into existing research workflows as the manufacturing of organoids is capital- and time-intensive. Owing to this, the adoption of organoids in ongoing drug screening and drug discovery activities is limited. This is a major issue as the ongoing drug screening and drug discovery processes will take a long time (up to a few years) to complete.
Organoids are showcasing significant potential in terms of further miniaturizing systems and enabling greater cost reductions in the drug discovery and development process. In spite of these advantages, it is expected to take a few years for this technology to completely replace conventional models. Till the time this scenario persists, organoid manufacturers are expected to witness sporadic growth and may largely be sidelined by conventional technology providers
Opportunityies Increasing focus on drug discovery activities
The increasing demand for new and advanced drugs is driving the overall pace of drug discovery and research. This is the major factor responsible for the rising number of clinical trials conducted for studying and commercializing new drugs. According to ClinicalTrials.gov, the total number of clinical trial studies in 2020 was estimated at 356,282.
A recent study conducted by the Hubrecht Institute states that organoids have the potential to make expensive drugs more cost-effective by identifying patients who are not likely to benefit from the drug. The significant growth in the number of clinical trials across the globe is expected to drive the demand for advanced medical technologies, including organoid models.
Challenges: Dearth of skilled professionals
Skilled professionals, such as researchers and technicians, are required to set up and run experiments involving organoids, and further make observations, obtain results, and analyze the obtained data. The lack of knowledge regarding the underlying scientific principles and the right choice of technique may result in several direct and indirect expenses and increase the workload and time pressure on researchers and service providers. Thus, there is a need for highly skilled personnel for interpretation, method development, validation, operation, and troubleshooting activities.
According to the US Bureau of Labor Statistics, the US economy faces a shortage of STEM (science, technology, engineering, and mathematics) professionals. As per the US Bureau of Labor Statistics, there is a dearth of skilled professionals in the fields of medical research, pharmaceuticals, and sciences. Several European countries, which are among the early adopters of new technologies in the life sciences sector, are facing similar challenges due to the shortage of graduates in STEM fields. Similarly, in India, the shortage of skilled talent in the STEM sector has increased from 6% in January 2014 to 12% in January 2018. This is considered a major challenge in the organoids market.
To know about the assumptions considered for the study, download the pdf brochure
By product, liver segment is expected to have the largest market share during the forecast period
The large share of this segment is attributed to factors such as the significant adoption of new technologies among researchers and academia (coupled with growing industry-academia collaborations for genomic research), technological advancements in the field of 3D bioprinting and the increased number of liver tranplants and diseases.
Delelopmental biology is the largest application segment of the human orgnaoids market
Developmental biology includes the production of gametes, fertilization, development of the embryo, emergence of the adult organism, and senescence. Organoids developed from stem cells or tissues in culture can be converted into structures that resemble the in vivo anatomy and physiology of intact organs. Human organoid cultures provide the potential to study the human development and model disease processes with the same depth of analysis customary for research with nonhuman model organisms. Technological advancements in the field of 3D bioprinting have shown huge potential for organ development as the culture time is very less compared to traditional methods of tissue culture. Patient-derived human organoid studies may accelerate medical research, creating new opportunities for tissue engineering and regenerative medicine and generating knowledge and tools for preclinical studies, including drug development and testing.
Pharceuticals & Biotechnology companies accounted for the largest share of the human organoids market, by end users, in 2020
Pharmaceutical and biotechnology companies mainly focus on developing new drugs for the treatment of various rare diseases. These companies need to submit specific data related to drug development during the drug development process and subsequent filing of applications to regulatory bodies. This necessitates a wide spectrum of services in the early development phases and clinical phases to comply with regulatory requirements. Technical and regulatory challenges related to the development of new drug molecules create complexities for pharmaceutical and biotechnology companies in terms of time and cost. However, due to strict regulations, companies often produce technologically superior products with better safety norms.
North America is the largest regional market for Human Organoids
North America (comprising the US and Canada) dominates the human orgnaoids market. North America is a mature market, with high penetration of human organoids technologies among key end users (pharmaceuticals & biotechnology companies, CROs, academia and others) and well-established distribution channels for human organoids product manufacturers and suppliers. Easy accessibility to and the high adoption of advanced technologies due to the significant per capita annual healthcare expenditure by the US and Canadian governments, as well as supportive government regulations, are driving the growth of the human organoids market in this region.
Key Market Players
BioIVT (US), Thermo Fisher Scientific (US), ZenBio (US), Corning (US), Organovo (US), Cyprio (France), Biopredic International (France), CELLINK (Sweden), Emulate (US), Hµrel Corporation (US), InSphero (Switzerland), Kerafast (US), Kirkstall (UK), and MIMETAS (Netherlands).
BioIVT founded in 1981 and is headquartered in New York, US. The company is a leading global provider of biological specimens, including human tissues, cell products, blood, and other biofluids. The company provides a wide range of services, ranging from target and biomarker validation, phenotypic assays to characterize novel therapeutics, and clinical assay development to in vitro hepatic modeling solutions. It is a supplier of ADME-Tox model systems, including hepatocytes and subcellular fractions, to better understand the pharmacokinetics and drug metabolism of newly discovered compounds and the effects on disease processes.
Some of the major end users of the company’s products are research organizations, pharmaceutical and biotechnological companies, medical device companies, and academic research institutes. BioIVT offers its products and services across North America, the Asia Pacific, Europe, and the Middle East & Africa. The company has two distributors in the Asia Pacific region, namely, Veritas Corporation (Japan) and Research Institute for Liver Diseases (Shanghai) Co., Ltd. (China).
Want to explore hidden markets that can drive new revenue in Human Organoids Market?
Scope of the Report
Want to explore hidden markets that can drive new revenue in Human Organoids Market?
|
Report Metric |
Details |
|
Market Size Available for Years |
2017–2025 |
|
Base Year Considered |
2019 |
|
Forecast Period |
2020–2025 |
|
Forecast Units |
Value (USD Million) |
|
Segments Covered |
Product, Application, Usability, End Users and Region |
|
Geographies Covered |
North America (US & Canada), Europe (Germany, the UK, France, Italy, Spain, and RoE), APAC (Japan, China, India, and the RoAPAC), LATAM (Brazil, Mexico, and RoLATAM), and MEA |
|
Companies Covered |
BioIVT (US), Thermo Fisher Scientific (US), Corning Incorporated (US), ZenBio (US), Organovo (US), InSphero (Switzerland), Kaly-Cell (France), STEMCELL Technologies (Canada), Hµrel Corporation (US), CELLINK (US), Kirkstall (US), PRIMACYT Cell Culture Technology (Germany, Cyprio (UK), Biopredic International (France), Kerafast (US), CN Bio Innovations (UK), MIMETAS (Netherlands), Pandorum Technologies (India), Promethera Biosciences (Belgium), Miromatrix (US), System1 Biosciences, Inc. (US), and Cyfuse Biomedical (Japan) |
This research report categorizes the human organoids market based on product, application, usabilty, end user, and region.
By Product
- Liver
- Kidney
- Pancreas
- Colorectal
- Heart
- Others
By Application
- Developmental biology
- Drug toxicity & efficacy testing
- Disease pathology
- Personalized medicine
- Regenerative medicine
- Other application
By Usabilty
- Ready to use products
- Customizable products
By End Users
- Pharmaceutical & Biotechnology companies
- CROs
- Academic & Research Institutes
- Others
By Region
-
North America
- US
- Canada
-
Europe
- Germany
- UK
- France
- Italy
- Spain
- RoE
-
Asia Pacific
- Japan
- China
- India
- RoAPAC
-
Latin America
- Brazil
- Mexico
- Rest of Latin America
- Middle East and Africa
Recent Developments
- In 2020, BIOIVT (US) partnered with upcyte technologies GmbH (Germany) as the exclusive commercial worldwide distributor for its cell products and media, including cells derived from hepatocytes and liver sinusoidal endothelial cells (LSECs).
- In 2019, Hurel and Cyprotex came into partnership which enabled Cyprotex to independently validate the HµREL multi-donor coculture model for clearance studies.
- In 2019, Organovo collaborated with MCRI and Leiden University Medical Center to develop stem cell-based bioprinted tissue treatment for kidney diseases..
- In 2018, Absolute Antibody merged with Kerafast to increase access to unique reagents.
Frequently Asked Questions (FAQ):
What are the drivers for the human organoids market?
The growth in the clinical microbiology market is driven majorly by the rising incidence of tranplants and technological advancements in the human organoids, and increased funding and public-private investments
Which segment provides the most opportunity for growth?
Liver segment by type will show the most opportunity for growth.
Who are the leading vendors operating in this market?
BioIVT (US), Thermo Fisher Scientific (US), ZenBio (US), Corning (US), Organovo (US), Cyprio (France), Biopredic International (France), CELLINK (Sweden), Emulate (US), Hµrel Corporation (US), InSphero (Switzerland), Kerafast (US), Kirkstall (UK), and MIMETAS (Netherlands) are the major vendors in the market
Which region is expected to witness significant demand for human orgnaoids in the coming years?
The Asia Pacific is the fastest-growing geographic segment in human organoids market, with a CAGR of 18.8% during the forecast period. Rising healthcare expenditure; the increasing number of hospitals and CROs in India and China; expanding research base across India, China, and Japan; government efforts to increase awareness related to human organodis; supportive regulations for the development and commercialization of advanced human orgnaoids products; and the increasing incidence of transplants are driving the growth of the APAC human organoids market.
What is the COVID 19 impact on human organoids in the coming years?
The COVID-19 pandemic has affected the human organoids market. The market is facing challenges in the manufacturing and supply chain, such as delivering products to end users in a timely manner as well as attending to an uneven demand for the products and services in the sector. In addition, a dearth of skilled lab professionals to conduct/study diagnostic tests, limited operations in most of the industries, inadequate funding for research and academic institutes, temporary closure of major academic institutes, disrupted supply chain, and challenges in providing essential/post-sales services due to lockdowns have led to the reduced supply of human orgnaoids products to end users. .
To speak to our analyst for a discussion on the above findings, click Speak to Analyst
Exclusive indicates content/data unique to MarketsandMarkets and not available with any competitors.
TABLE OF CONTENTS
1 INTRODUCTION (Page No. - 19)
1.1 OBJECTIVES OF THE STUDY
1.2 MARKET DEFINITION
TABLE 1 INCLUSIONS & EXCLUSIONS
1.3 MARKET SCOPE
1.3.1 MARKETS COVERED
1.3.2 YEARS CONSIDERED FOR THE STUDY
1.4 CURRENCY
1.5 STAKEHOLDERS
1.6 SUMMARY OF CHANGES
2 RESEARCH METHODOLOGY (Page No. - 22)
2.1 RESEARCH DATA
FIGURE 1 RESEARCH DESIGN
2.1.1 SECONDARY DATA
2.1.1.1 Secondary sources
2.1.2 PRIMARY DATA
FIGURE 2 BREAKDOWN OF PRIMARIES: HUMAN ORGANOIDS MARKET
2.2 MARKET ESTIMATION METHODOLOGY
FIGURE 3 RESEARCH METHODOLOGY: HYPOTHESIS BUILDING
2.2.1 REVENUE MAPPING-BASED MARKET ESTIMATION
2.2.2 PROCEDURE-BASED MARKET ESTIMATION
FIGURE 4 MARKET SIZE ESTIMATION: HUMAN ORGANOIDS MARKET
2.2.3 PRIMARY RESEARCH VALIDATION
2.3 DATA TRIANGULATION
FIGURE 5 DATA TRIANGULATION METHODOLOGY
2.4 RESEARCH ASSUMPTIONS
2.5 RESEARCH LIMITATIONS
3 EXECUTIVE SUMMARY (Page No. - 31)
FIGURE 6 HUMAN ORGANOIDS MARKET, BY PRODUCT, 2020 VS. 2025 (USD MILLION)
FIGURE 7 HUMAN ORGANOIDS MARKET, BY APPLICATION, 2020 VS. 2025 (USD MILLION)
FIGURE 8 HUMAN ORGANOIDS MARKET SHARE, BY END USER, 2020 VS. 2025
FIGURE 9 GEOGRAPHICAL SNAPSHOT OF THE HUMAN ORGANOIDS MARKET
4 PREMIUM INSIGHTS (Page No. - 34)
4.1 HUMAN ORGANOIDS MARKET OVERVIEW
FIGURE 10 GROWING FOCUS ON DEVELOPING ALTERNATIVES FOR ANIMAL TESTING MODELS TO DRIVE MARKET GROWTH
4.2 HUMAN ORGANOIDS MARKET, BY PRODUCT, 2020 VS. 2025 (USD MILLION)
FIGURE 11 LIVER ORGANOIDS ARE EXPECTED TO DOMINATE THE HUMAN ORGANOID PRODUCTS MARKET
4.3 ASIA PACIFIC: HUMAN ORGANOIDS MARKET, BY END USER & COUNTRY (2019)
FIGURE 12 PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES ACCOUNTED FOR THE LARGEST SHARE OF THE APAC HUMAN ORGANOIDS MARKET IN 2019
4.4 GEOGRAPHIC ANALYSIS: HUMAN ORGANOIDS MARKET, BY USABILITY (2019)
FIGURE 13 READY-TO-USE PRODUCTS SEGMENT DOMINATES THE GLOBAL HUMAN ORGANOIDS MARKET
4.5 HUMAN ORGANOIDS MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES
FIGURE 14 ASIA PACIFIC TO REGISTER THE HIGHEST CAGR DURING THE FORECAST PERIOD
5 MARKET OVERVIEW (Page No. - 38)
5.1 INTRODUCTION
5.2 MARKET DYNAMICS
FIGURE 15 HUMAN ORGANOIDS MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, & CHALLENGES
5.2.1 DRIVERS
5.2.1.1 Growing focus on developing alternatives for animal testing models
5.2.1.2 Significant increase in research funding and venture capital investments for the development of human organoids
5.2.1.3 Growing initiatives to increase awareness about organoids
TABLE 2 GROWING INITIATIVES AND EVENTS FOR ORGANOIDS
5.2.1.4 Increasing research activities on organoids
TABLE 3 RESEARCH PROJECTS AND ACTIVITIES
5.2.1.5 Increasing prevalence of non-alcoholic fatty liver disease
5.2.1.6 Growing need for the early detection of drug toxicity to minimize financial losses due to late-stage drug failure
5.2.2 RESTRAINTS
5.2.2.1 Issues related to the incorporation of organoids into existing workflows
5.2.3 OPPORTUNITIES
5.2.3.1 Increasing focus on drug discovery activities
5.2.3.2 Rising demand for organ transplantation
5.2.3.3 Growing healthcare market in the Asia Pacific and Latin America
5.2.4 CHALLENGES
5.2.4.1 Dearth of skilled professionals
5.3 IMPACT OF THE COVID-19 PANDEMIC ON THE HUMAN ORGANOIDS MARKET
5.4 REGULATORY SCENARIO
5.5 ECOSYSTEM COVERAGE
5.6 TECHNOLOGY ANALYSIS
5.7 PRICING ANALYSIS
6 HUMAN ORGANOIDS MARKET, BY PRODUCT (Page No. - 49)
6.1 INTRODUCTION
TABLE 4 HUMAN ORGANOIDS MARKET, BY PRODUCT, 2018-2025 (USD MILLION)
6.2 LIVER
TABLE 5 HUMAN LIVER ORGANOIDS MARKET, BY TYPE, 2018-2025 (USD MILLION)
6.2.1 2D LIVER MODELS
TABLE 6 2D LIVER MODELS MARKET, BY TYPE, 2018-2025 (USD MILLION)
6.2.1.1 Fresh hepatocytes
TABLE 7 FRESH HEPATOCYTES MARKET, BY REGION, 2018-2025 (USD MILLION)
6.2.1.2 Cryopreserved hepatocytes
TABLE 8 CRYOPRESERVED HEPATOCYTES MARKET, BY REGION, 2018-2025 (USD MILLION)
6.2.1.3 Other 2D liver models
TABLE 9 OTHER 2D LIVER MODELS MARKET, BY REGION, 2018-2025 (USD MILLION)
6.2.2 3D LIVER MODELS
TABLE 10 3D LIVER MODELS MARKET, BY TYPE, 2018-2025 (USD MILLION)
TABLE 11 3D LIVER MODELS MARKET, BY REGION, 2018-2025 (USD MILLION)
6.2.2.1 Liver organoids
TABLE 12 LIVER ORGANOIDS MARKET, BY REGION, 2018-2025 (USD MILLION)
6.2.2.2 3D bioprinted liver
TABLE 13 3D BIOPRINTED LIVER MARKET, BY REGION, 2018-2025 (USD MILLION)
6.2.2.3 Spheroids
TABLE 14 LIVER SPHEROIDS MARKET, BY REGION, 2018-2025 (USD MILLION)
6.2.2.4 Liver-on-a-chip
TABLE 15 LIVER-ON-A-CHIP MARKET, BY REGION, 2018-2025 (USD MILLION)
6.2.2.5 Other 3D liver models
TABLE 16 OTHER 3D LIVER MODELS MARKET, BY REGION, 2018-2025 (USD MILLION)
6.3 KIDNEY
TABLE 17 HUMAN KIDNEY ORGANOIDS MARKET, BY TYPE, 2018-2025 (USD MILLION)
6.3.1 2D KIDNEY MODELS
TABLE 18 2D KIDNEY MODELS MARKET, BY TYPE, 2018-2025 (USD MILLION)
6.3.1.1 Fresh kidney cells
TABLE 19 FRESH KIDNEY CELLS MARKET, BY REGION, 2018-2025 (USD MILLION)
6.3.1.2 Cryopreserved cells
TABLE 20 KIDNEY CRYOPRESERVED CELLS MARKET, BY REGION, 2018-2025 (USD MILLION)
6.3.1.3 Other 2D kidney models
TABLE 21 OTHER 2D KIDNEY MODELS MARKET, BY REGION, 2018-2025 (USD MILLION)
6.3.2 3D KIDNEY MODELS
TABLE 22 3D KIDNEY MODELS MARKET, BY TYPE, 2018-2025 (USD MILLION)
TABLE 23 3D KIDNEY MODELS MARKET, BY REGION, 2018-2025 (USD MILLION)
6.3.2.1 Organoids
TABLE 24 KIDNEY ORGANOIDS MARKET, BY REGION, 2018-2025 (USD MILLION)
6.3.2.2 3D bioprinted kidney
TABLE 25 3D BIOPRINTED KIDNEY MARKET, BY REGION, 2018-2025 (USD MILLION)
6.3.2.3 Spheroids
TABLE 26 KIDNEY SPHEROIDS MARKET, BY REGION, 2018-2025 (USD MILLION)
6.3.2.4 Other 3D kidney models
TABLE 27 OTHER 3D KIDNEY MODELS MARKET, BY REGION, 2018-2025 (USD MILLION)
6.4 PANCREAS
TABLE 28 HUMAN PANCREAS ORGANOIDS MARKET, BY TYPE, 2018-2025 (USD MILLION)
6.4.1 2D PANCREATIC MODELS
TABLE 29 2D PANCREATIC MODELS MARKET, BY TYPE, 2018-2025 (USD MILLION)
6.4.1.1 Cryopreserved cells
TABLE 30 PANCREATIC CRYOPRESERVED CELLS MARKET, BY REGION, 2018-2025 (USD MILLION)
6.4.1.2 Fresh cells
TABLE 31 PANCRATIC FRESH CELLS MARKET, BY REGION, 2018-2025 (USD MILLION)
6.4.1.3 Other 2D pancreatic models
TABLE 32 OTHER 2D PANCREATIC MODELS MARKET, BY REGION, 2018-2025 (USD MILLION)
6.4.2 3D PANCREATIC MODELS
TABLE 33 3D PANCREATIC MODELS MARKET, BY TYPE, 2018-2025 (USD MILLION)
TABLE 34 3D PANCREATIC MODELS MARKET, BY REGION, 2018-2025 (USD MILLION)
6.4.2.1 Organoids
TABLE 35 PANCREATIC ORGANOIDS MARKET, BY REGION, 2018-2025 (USD MILLION)
6.4.2.2 3D bioprinted pancreas
TABLE 36 3D BIOPRINTED PANCREAS MARKET, BY REGION, 2018-2025 (USD MILLION)
6.4.2.3 Spheroids
TABLE 37 PANCREATIC SPHEROIDS MARKET, BY REGION, 2018-2025 (USD MILLION)
6.4.2.4 Other 3D pancreatic models
TABLE 38 OTHER 3D PANCREATIC MODELS MARKET, BY REGION, 2018-2025 (USD MILLION)
6.5 COLORECTAL
TABLE 39 HUMAN COLORECTAL ORGANOIDS MARKET, BY TYPE, 2018-2025 (USD MILLION)
6.5.1 2D COLORECTAL MODELS
TABLE 40 2D COLORECTAL MODELS MARKET, BY TYPE, 2018-2025 (USD MILLION)
6.5.1.1 Fresh cells
TABLE 41 COLORECTAL FRESH CELLS MARKET, BY REGION, 2018-2025 (USD MILLION)
6.5.1.2 Cryopreserved cells
TABLE 42 COLORECTAL CRYOPRESERVED CELLS MARKET, BY REGION, 2018-2025 (USD MILLION)
6.5.1.3 Other 2D colorectal models
TABLE 43 OTHER 2D COLORECTAL MODELS MARKET, BY REGION, 2018-2025 (USD MILLION)
6.5.2 3D COLORECTAL MODELS
TABLE 44 3D COLORECTAL MODELS MARKET, BY TYPE, 2018-2025 (USD MILLION)
TABLE 45 3D COLORECTAL MODELS MARKET, BY REGION, 2018-2025 (USD MILLION)
6.5.2.1 Organoids
TABLE 46 COLORECTAL ORGANOIDS MARKET, BY REGION, 2018-2025 (USD MILLION)
6.5.2.2 3D bioprinted models
TABLE 47 COLORECTAL 3D BIOPRINTED MODELS MARKET, BY REGION, 2018-2025 (USD MILLION)
6.5.2.3 Spheroids
TABLE 48 COLORECTAL SPHEROIDS MARKET, BY REGION, 2018-2025 (USD MILLION)
6.5.2.4 Other 3D colorectal models
TABLE 49 OTHER 3D COLORECTAL MODELS MARKET, BY REGION, 2018-2025 (USD MILLION)
6.6 HEART
TABLE 50 HUMAN HEART ORGANOIDS MARKET, BY TYPE, 2018-2025 (USD MILLION)
6.6.1 2D HEART MODELS
TABLE 51 2D HEART MODELS MARKET, BY TYPE, 2018-2025 (USD MILLION)
6.6.1.1 Fresh cells
TABLE 52 HEART FRESH CELLS MARKET, BY REGION, 2018-2025 (USD MILLION)
6.6.1.2 Cryopreserved cells
TABLE 53 HEART CRYOPRESERVED CELLS MARKET, BY REGION, 2018-2025 (USD MILLION)
6.6.1.3 Other 2D heart models
TABLE 54 OTHER 2D HEART MODELS MARKET, BY REGION, 2018-2025 (USD MILLION)
6.6.2 3D HEART MODELS
TABLE 55 3D HEART MODELS MARKET, BY TYPE, 2018-2025 (USD MILLION)
TABLE 56 3D HEART MODELS MARKET, BY REGION, 2018-2025 (USD MILLION)
6.6.2.1 Organoids
TABLE 57 HEART ORGANOIDS MARKET, BY REGION, 2018-2025 (USD MILLION)
6.6.2.2 3D bioprinted heart
TABLE 58 3D BIOPRINTED HEART MARKET, BY REGION, 2018-2025 (USD MILLION)
6.6.2.3 Spheroids
TABLE 59 HEART SPHEROIDS MARKET, BY REGION, 2018-2025 (USD MILLION)
6.6.2.4 Other 3D heart models
TABLE 60 OTHER 3D HEART MODELS MARKET, BY REGION, 2018-2025 (USD MILLION)
6.7 OTHER PRODUCTS
TABLE 61 HUMAN ORGANOIDS MARKET FOR OTHER PRODUCTS, BY TYPE, 2018-2025 (USD MILLION)
6.7.1 2D MODELS
TABLE 62 OTHERS 2D MODELS MARKET, BY TYPE, 2018-2025 (USD MILLION)
6.7.1.1 Fresh cells
TABLE 63 OTHERS FRESH CELLS MARKET, BY REGION, 2018-2025 (USD MILLION)
6.7.1.2 Cryopreserved cells
TABLE 64 OTHERS CRYOPRESERVED CELLS MARKET, BY REGION, 2018-2025 (USD MILLION)
6.7.1.3 Other 2D models
TABLE 65 OTHERS OTHER 2D MODELS MARKET, BY REGION, 2018-2025 (USD MILLION)
6.7.2 3D MODELS
TABLE 66 OTHERS 3D MODELS MARKET, BY TYPE, 2018-2025 (USD MILLION)
TABLE 67 3D OTHER MODELS MARKET, BY REGION, 2018-2025 (USD MILLION)
6.7.2.1 Organoids
TABLE 68 OTHERS ORGANOIDS MARKET, BY REGION, 2018-2025 (USD MILLION)
6.7.2.2 3D bioprinted models
TABLE 69 OTHERS 3D BIOPRINTED MODELS MARKET, BY REGION, 2018-2025 (USD MILLION)
6.7.2.3 Spheroids
TABLE 70 OTHERS SPHEROIDS MARKET, BY REGION, 2018-2025 (USD MILLION)
6.7.2.4 Other 3D models
TABLE 71 OTHERS OTHER 3D MODELS MARKET, BY REGION, 2018-2025 (USD MILLION)
7 HUMAN ORGANOIDS MARKET, BY USABILITY (Page No. - 90)
7.1 INTRODUCTION
TABLE 72 HUMAN ORGANOIDS MARKET, BY USABILITY, 2018-2025 (USD MILLION)
7.2 READY-TO-USE PRODUCTS
7.2.1 READY-TO-USE PRODUCTS SEGMENT TO DOMINATE THE MARKET AS THEY CAN BE MASS PRODUCED
TABLE 73 HUMAN ORGANOIDS MARKET FOR READY-TO-USE PRODUCTS, BY REGION, 2018-2025 (USD MILLION)
7.3 CUSTOMIZABLE PRODUCTS
7.3.1 CUSTOMIZABLE PRODUCTS CAN FULFIL THE REQUIREMENT FOR A SPECIFIC NEED OF ORGAN TRANSPLANTATION
TABLE 74 HUMAN ORGANOIDS MARKET FOR CUSTOMIZABLE PRODUCTS, BY REGION, 2018-2025 (USD MILLION)
8 HUMAN ORGANOIDS MARKET, BY APPLICATION (Page No. - 94)
8.1 INTRODUCTION
TABLE 75 HUMAN ORGANOIDS MARKET, BY APPLICATION, 2018-2025 (USD MILLION)
8.2 DEVELOPMENTAL BIOLOGY
8.2.1 TECHNOLOGICAL ADVANCEMENTS IN THE FIELD OF 3D BIOPRINTING WILL BOOST MARKET GROWTH
TABLE 76 HUMAN ORGANOIDS MARKET FOR DEVELOPMENTAL BIOLOGY, BY REGION, 2018-2025 (USD MILLION)
8.3 DRUG TOXICITY & EFFICACY TESTING
8.3.1 DRUG TOXICITY & EFFICACY TESTING WILL WITNESS GROWTH AS ORGANOIDS SHOW HIGH RESISTANCE TOWARDS CLINICAL DOSES
TABLE 77 HUMAN ORGANOIDS MARKET FOR DRUG TOXICITY & EFFICACY TESTING, BY REGION, 2018-2025 (USD MILLION)
8.4 DISEASE PATHOLOGY
8.4.1 DEVELOPMENT OF INTESTINAL ORGANOIDS TO SUPPORT MARKET GROWTH
TABLE 78 HUMAN ORGANOIDS MARKET FOR DISEASE PATHOLOGY, BY REGION, 2018-2025 (USD MILLION)
8.5 PERSONALIZED MEDICINE
8.5.1 HIGH COST OF DEVELOPING ORGANOIDS TO HAMPER MARKET GROWTH
TABLE 79 HUMAN ORGANOIDS MARKET FOR PERSONALIZED MEDICINE, BY REGION, 2018-2025 (USD MILLION)
8.6 REGENERATIVE MEDICINE
8.6.1 ORGANOIDS HOLD A HUGE POTENTIAL IN REGENERATIVE MEDICINE PURPOSES
TABLE 80 HUMAN ORGANOIDS MARKET FOR REGENERATIVE MEDICINE, BY REGION, 2018-2025 (USD MILLION)
8.7 OTHER APPLICATIONS
TABLE 81 HUMAN ORGANOIDS MARKET FOR OTHER APPLICATIONS, BY REGION, 2018-2025 (USD MILLION)
9 HUMAN ORGANOIDS MARKET, BY END USER (Page No. - 102)
9.1 INTRODUCTION
TABLE 82 HUMAN ORGANOIDS MARKET, BY END USER, 2018-2025 (USD MILLION)
9.2 PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES
9.2.1 PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES ARE THE LARGEST END USERS OF HUMAN ORGANOID PRODUCTS
TABLE 83 HUMAN ORGANOIDS MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY REGION, 2018-2025 (USD MILLION)
9.3 CONTRACT RESEARCH ORGANIZATIONS
9.3.1 INCREASING OUTSOURCING OF CLINICAL RESEARCH SERVICES BY PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES TO SUPPORT MARKET GROWTH
TABLE 84 HUMAN ORGANOIDS MARKET FOR CONTRACT RESEARCH ORGANIZATIONS, BY REGION, 2018-2025 (USD MILLION)
9.4 ACADEMIC & RESEARCH INSTITUTES
9.4.1 HIGH COST OF TECHNOLOGICALLY ADVANCED ORGANOIDS IS EXPECTED TO HAMPER MARKET GROWTH FOR THESE FACILITIES
TABLE 85 HUMAN ORGANOIDS MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY REGION, 2018-2025 (USD MILLION)
9.5 OTHER END USERS
TABLE 86 HUMAN ORGANOIDS MARKET FOR OTHER END USERS, BY REGION, 2018-2025 (USD MILLION)
10 HUMAN ORGANOIDS MARKET, BY REGION (Page No. - 107)
10.1 INTRODUCTION
TABLE 87 HUMAN ORGANOIDS MARKET, BY REGION, 2018-2025 (USD MILLION)
10.2 NORTH AMERICA
FIGURE 16 NORTH AMERICA: HUMAN ORGANOIDS MARKET SNAPSHOT
TABLE 88 NORTH AMERICA: HUMAN ORGANOIDS MARKET, BY COUNTRY, 2018-2025 (USD MILLION)
TABLE 89 NORTH AMERICA: HUMAN LIVER ORGANOIDS MARKET, BY TYPE, 2018-2025 (USD MILLION)
TABLE 90 NORTH AMERICA: HUMAN LIVER ORGANOIDS MARKET FOR 2D MODELS, BY TYPE, 2018-2025 (USD MILLION)
TABLE 91 NORTH AMERICA: HUMAN LIVER ORGANOIDS MARKET FOR 3D MODELS, BY TYPE, 2018-2025 (USD MILLION)
TABLE 92 NORTH AMERICA: HUMAN ORGANOIDS MARKET, BY APPLICATION, 2018-2025 (USD MILLION)
TABLE 93 NORTH AMERICA: HUMAN ORGANOIDS MARKET, BY USABILITY, 2018-2025 (USD MILLION)
TABLE 94 NORTH AMERICA: HUMAN ORGANOIDS MARKET, BY END USER, 2018-2025 (USD MILLION)
10.2.1 US
10.2.1.1 Ongoing technological advancements in the field of transplantation to drive market growth in the US
TABLE 95 US: HUMAN LIVER ORGANOIDS MARKET, BY TYPE, 2018-2025 (USD MILLION)
10.2.2 CANADA
10.2.2.1 Growing availability of human organoid products to support market growth in Canada
TABLE 96 CANADA: HUMAN LIVER ORGANOIDS MARKET, BY TYPE, 2018-2025 (USD MILLION)
10.3 EUROPE
TABLE 97 EUROPE: HUMAN ORGANOIDS MARKET, BY COUNTRY, 2018-2025 (USD MILLION)
TABLE 98 EUROPE: HUMAN LIVER ORGANOIDS MARKET, BY TYPE, 2018-2025 (USD MILLION)
TABLE 99 EUROPE: HUMAN LIVER ORGANOIDS MARKET FOR 2D MODELS, BY TYPE, 2018-2025 (USD MILLION)
TABLE 100 EUROPE: HUMAN LIVER ORGANOIDS MARKET FOR 3D MODELS, BY TYPE, 2018-2025 (USD MILLION)
TABLE 101 EUROPE: HUMAN ORGANOIDS MARKET, BY APPLICATION, 2018-2025 (USD MILLION)
TABLE 102 EUROPE: HUMAN ORGANOIDS MARKET, BY USABILITY, 2018-2025 (USD MILLION)
TABLE 103 EUROPE: HUMAN ORGANOIDS MARKET, BY END USER, 2018-2025 (USD MILLION)
10.3.1 GERMANY
10.3.1.1 Germany dominates the European human organoids market
TABLE 104 GERMANY: HUMAN LIVER ORGANOIDS MARKET, BY TYPE, 2018-2025 (USD MILLION)
10.3.2 UK
10.3.2.1 Rising number of transplantation procedures to drive market growth in the UK
TABLE 105 UK: NUMBER OF TRANSPLANTATION PROCEDURES, BY ORGAN TYPE, 2018
TABLE 106 UK: HUMAN LIVER ORGANOIDS MARKET, BY TYPE, 2018-2025 (USD MILLION)
10.3.3 FRANCE
10.3.3.1 Adoption of molecular diagnostic techniques for donor-recipient compatibility testing is increasing in France
TABLE 107 FRANCE: HUMAN LIVER ORGANOIDS MARKET, BY TYPE, 2018-2025 (USD MILLION)
10.3.4 ITALY
10.3.4.1 Sluggish growth in the Italian healthcare sector to restrain the market growth
TABLE 108 ITALY: HUMAN LIVER ORGANOIDS MARKET, BY TYPE, 2018-2025 (USD MILLION)
10.3.5 SPAIN
10.3.5.1 Rising number of solid organ transplantation procedures to drive market growth in Spain
TABLE 109 SPAIN: HUMAN LIVER ORGANOIDS MARKET, BY TYPE, 2018-2025 (USD MILLION)
10.3.6 REST OF EUROPE
TABLE 110 ROE: HUMAN LIVER ORGANOIDS MARKET, BY TYPE, 2018-2025 (USD MILLION)
10.4 ASIA PACIFIC
FIGURE 17 ASIA PACIFIC: HUMAN ORGANOIDS MARKET SNAPSHOT
TABLE 111 ASIA PACIFIC: HUMAN ORGANOIDS MARKET, BY COUNTRY, 2018-2025 (USD MILLION)
TABLE 112 ASIA PACIFIC: HUMAN LIVER ORGANOIDS MARKET, BY TYPE, 2018-2025 (USD MILLION)
TABLE 113 ASIA PACIFIC: HUMAN LIVER ORGANOIDS MARKET FOR 2D MODELS, BY TYPE, 2018-2025 (USD MILLION)
TABLE 114 ASIA PACIFIC: HUMAN LIVER ORGANOIDS MARKET FOR 3D MODELS, BY TYPE, 2018-2025 (USD MILLION)
TABLE 115 ASIA PACIFIC: HUMAN ORGANOIDS MARKET, BY APPLICATION, 2018-2025 (USD MILLION)
TABLE 116 ASIA PACIFIC: HUMAN ORGANOIDS MARKET, BY USABILITY, 2018-2025 (USD MILLION)
TABLE 117 ASIA PACIFIC: HUMAN ORGANOIDS MARKET, BY END USER, 2018-2025 (USD MILLION)
10.4.1 JAPAN
10.4.1.1 Growth in biomedical & medical research to support market growth
TABLE 118 JAPAN: HUMAN LIVER ORGANOIDS MARKET, BY TYPE, 2018-2025 (USD MILLION)
10.4.2 CHINA
10.4.2.1 Healthcare infrastructure improvements to support market growth in China
TABLE 119 CHINA: NUMBER OF ORGAN TRANSPLANTATION PROCEDURES PERFORMED, 2018
TABLE 120 CHINA: HUMAN LIVER ORGANOIDS MARKET, BY TYPE, 2018-2025 (USD MILLION)
10.4.3 INDIA
10.4.3.1 Increasing number of transplantation procedures to drive market growth in India
TABLE 121 INDIA: HUMAN LIVER ORGANOIDS MARKET, BY TYPE, 2018-2025 (USD MILLION)
10.4.4 AUSTRALIA
10.4.4.1 Rising number of solid organ transplantation procedures to support market growth in Australia
TABLE 122 AUSTRALIA: HUMAN LIVER ORGANOIDS MARKET, BY TYPE, 2018-2025 (USD MILLION)
10.4.5 SOUTH KOREA
10.4.5.1 Government initiatives to introduce medical coverage for transplantation to support market growth in South Korea
TABLE 123 SOUTH KOREA: HUMAN LIVER ORGANOIDS MARKET, BY TYPE, 2018-2025 (USD MILLION)
10.4.6 REST OF ASIA PACIFIC
TABLE 124 ROAPAC: HUMAN LIVER ORGANOIDS MARKET, BY TYPE, 2018-2025 (USD MILLION)
10.5 LATIN AMERICA
TABLE 125 LATIN AMERICA: HUMAN ORGANOIDS MARKET, BY COUNTRY, 2018-2025 (USD MILLION)
TABLE 126 LATIN AMERICA: HUMAN LIVER ORGANOIDS MARKET, BY TYPE, 2018-2025 (USD MILLION)
TABLE 127 LATIN AMERICA: HUMAN LIVER ORGANOIDS MARKET FOR 2D MODELS, BY TYPE, 2018-2025 (USD MILLION)
TABLE 128 LATIN AMERICA: HUMAN LIVER ORGANOIDS MARKET FOR 3D MODELS, BY TYPE, 2018-2025 (USD MILLION)
TABLE 129 LATIN AMERICA: HUMAN ORGANOIDS MARKET, BY APPLICATION, 2018-2025 (USD MILLION)
TABLE 130 LATIN AMERICA: HUMAN ORGANOIDS MARKET, BY USABILITY, 2018-2025 (USD MILLION)
TABLE 131 LATIN AMERICA: HUMAN ORGANOIDS MARKET, BY END USER, 2018-2025 (USD MILLION)
10.5.1 BRAZIL
10.5.1.1 Brazil is the largest market for human organoids in Latin America
TABLE 132 BRAZIL: HUMAN LIVER ORGANOIDS MARKET, BY TYPE, 2018-2025 (USD MILLION)
10.5.2 MEXICO
10.5.2.1 Rising medical tourism to support market growth in Mexico
TABLE 133 MEXICO: HUMAN LIVER ORGANOIDS MARKET, BY TYPE, 2018-2025 (USD MILLION)
10.5.3 REST OF LATIN AMERICA
TABLE 134 ROLATAM: HUMAN LIVER ORGANOIDS MARKET, BY TYPE, 2018-2025 (USD MILLION)
10.6 MIDDLE EAST & AFRICA
10.6.1 DEVELOPING HEALTHCARE INFRASTRUCTURE TO PROPEL MARKET GROWTH
TABLE 135 MIDDLE EAST & AFRICA: HUMAN LIVER ORGANOIDS MARKET, BY TYPE, 2018-2025 (USD MILLION)
TABLE 136 MIDDLE EAST & AFRICA: HUMAN LIVER ORGANOIDS MARKET FOR 2D MODELS, BY TYPE, 2018-2025 (USD MILLION)
TABLE 137 MIDDLE EAST & AFRICA: HUMAN LIVER ORGANOIDS MARKET FOR 3D MODELS, BY TYPE, 2018-2025 (USD MILLION)
TABLE 138 MIDDLE EAST & AFRICA: HUMAN ORGANOIDS MARKET, BY APPLICATION, 2018-2025 (USD MILLION)
TABLE 139 MIDDLE EAST & AFRICA: HUMAN ORGANOIDS MARKET, BY USABILITY, 2018-2025 (USD MILLION)
TABLE 140 MIDDLE EAST & AFRICA: HUMAN ORGANOIDS MARKET, BY END USER, 2018-2025 (USD MILLION)
11 COMPETITIVE LANDSCAPE (Page No. - 137)
11.1 OVERVIEW
FIGURE 18 KEY DEVELOPMENTS IN THE HUMAN ORGANOIDS MARKET, 2017-2020
11.2 MARKET SHARE ANALYSIS
FIGURE 19 HUMAN ORGANOIDS MARKET SHARE, BY KEY PLAYER, 2019
11.3 COMPETITIVE SCENARIO
11.3.1 PRODUCT LAUNCHES
TABLE 141 PRODUCT LAUNCH, 2017-2020
11.3.2 AGREEMENTS, COLLABORATIONS, & PARTNERSHIPS
TABLE 142 AGREEMENTS, COLLABORATIONS & PARTNERSHIP, 2017-2020
11.3.3 MERGERS
TABLE 143 MERGERS, 2018
12 COMPANY EVALUATION MATRIX AND COMPANY PROFILES (Page No. - 141)
12.1 COMPANY EVALUATION MATRIX DEFINITION AND METHODOLOGY
12.1.1 STARS
12.1.2 EMERGING LEADERS
12.1.3 PERVASIVE
12.1.4 PARTICIPANTS
FIGURE 20 HUMAN ORGANOIDS MARKET: COMPETITIVE LEADERSHIP MAPPING, 2019
12.2 COMPANY PROFILES
(Business overview, Products offered & Recent developments)*
12.2.1 BIOIVT
12.2.2 CELLINK
FIGURE 21 CELLINK: COMPANY SNAPSHOT
12.2.3 CORNING INCORPORATED
FIGURE 22 CORNING INCORPORATED: COMPANY SNAPSHOT
12.2.4 CYTES BIOTECHNOLOGIES, S.L.
12.2.5 HµREL CORPORATION
12.2.6 INSPHERO
12.2.7 KALY-CELL
12.2.8 KIRKSTALL LTD.
12.2.9 MIMETAS B.V.
12.2.10 NEUROMICS
12.2.11 ORGANOVO
12.2.12 PRIMACYT CELL CULTURE TECHNOLOGY GMBH
12.2.13 STEMCELL TECHNOLOGIES INC.
12.2.14 THERMO FISHER SCIENTIFIC
FIGURE 23 THERMO FISHER SCIENTIFIC: COMPANY SNAPSHOT
12.2.15 ZENBIO, INC.
*Details on Business overview, Products offered & Recent developments might not be captured in case of unlisted companies.
12.3 EMERGING COMPANIES
12.3.1 BIOPREDIC INTERNATIONAL
12.3.2 CN BIO INNOVATIONS
12.3.3 CYPRIO
12.3.4 EMULATE, INC.
12.3.5 KERAFAST
13 APPENDIX (Page No. - 166)
13.1 DISCUSSION GUIDE
13.2 KNOWLEDGE STORE: MARKETSANDMARKETS' SUBSCRIPTION PORTAL
13.3 AVAILABLE CUSTOMIZATIONS
13.4 RELATED REPORTS
13.5 AUTHOR DETAILS
The study involved four major activities to estimate the current size of the human organoids market. Exhaustive secondary research was carried out to collect information on the market and its different subsegments. The next step was to validate these findings, assumptions, and sizing with industry experts across the value chain through primary research. Top-down and bottom-up approaches were employed to estimate the complete market size. Thereafter, market breakdown and data triangulation procedures were used to estimate the size of segments and subsegments.
Secondary Research
In the secondary research process, various secondary sources, such as annual reports, press releases & investor presentations of companies, white papers, certified publications, articles by recognized authors, gold-standard & silver-standard websites, regulatory bodies, and databases (such as D&B Hoovers, Bloomberg Business, and Factiva) were referred to in order to identify and collect information for the orthopedic braces and supports market study.
Primary Research
The human organoids market comprises several stakeholders such as Manufacturers of human organoid products, Healthcare service providers, Manufacturers of pharmaceutical products, Pharmaceutical and biotechnology companies, Clinical research organizations (CROs), Clinical testing laboratories, Public and private research organizations, Research laboratories and academic institutes, Market research and consulting firms The demand side of this market is characterized by the increasing incidence of transplants and technological advancements, and increased funding and public-private investments. Various primary sources from both the supply and demand sides of the market were interviewed to obtain qualitative and quantitative information. The following is the breakdown of primary respondents:
To know about the assumptions considered for the study, download the pdf brochure
Market Size Estimation
Both top-down and bottom-up approaches were used to estimate and validate the total size of the clinical microbiology market. These methods were also used extensively to estimate the size of various subsegments in the market. The research methodology used to estimate the market size includes the following:
- The key players in the industry and markets have been identified through extensive secondary research
- The industry’s supply chain and market size, in terms of value, have been determined through primary and secondary research
- All percentage shares, splits, and breakdowns have been determined using secondary sources and verified through primary sources
To know about the assumptions considered for the study, Request for Free Sample Report
Data Triangulation
After arriving at the overall market size—using the market size estimation processes as explained above—the human organoids market was split into several segments and subsegments. In order to complete the overall market engineering process and arrive at the exact statistics of each market segment and subsegment, data triangulation and market breakdown procedures were employed, wherever applicable. The data was triangulated by studying various factors and trends from both the demand and supply sides in the clinical microbiology industry.
Report Objectives
- To define, describe, and forecast the global human organoids market on the basis of product, usability, application, end user, and region
- To provide detailed information regarding the major factors influencing the market growth (such as drivers, restraints, opportunities, and challenges)
- To strategically analyze micromarkets1 with respect to individual growth trends, future prospects, and contributions to the overall market
- To analyze the opportunities in the market for key stakeholders and provide details of the competitive landscape for major market leaders
- To forecast the size of the market segments with respect to five main regions, namely, North America (the US and Canada), Europe (Germany, the UK, France, Italy, Spain, and Rest of Europe), Asia Pacific (Japan, China, India, Australia, South Korea, and Rest of Asia Pacific), Latin America (Brazil, Mexico, and Rest of Latin America), and the Middle East & Africa
- To profile the key market players and comprehensively analyze their market shares and core competencies2
- To track and analyze competitive developments such as mergers and acquisitions, new product developments, partnerships, agreements, collaborations, and expansions in the global human organoids market
Available Customizations
With the given market data, MarketsandMarkets offers customizations as per the company’s specific needs. The following customization options are available for the human organoids market report:
PRODUCT ANALYSIS
- Product Matrix, which gives a detailed comparison of the product portfolios of the top five global players
PRODUCT ANALYSIS
- Further breakdown of the Rest of European market into Poland, Nederland and other European countries (aggregated)
COMPANY INFORMATION
- Detailed analysis and profiling of additional market players (up to 5 OEMs)
Generating Response ...
Growth opportunities and latent adjacency in Human Organoids Market